Table 1.
Described effects of inhibitors of the indicated epigenetic targets and targeted domains in immuno-oncology-related pathways.
| Target | Domain | Immuno-Modulatory Effects |
|---|---|---|
| DNMTs | Methyltransferase | Upregulation of PD-L1/PD-L2 in cancer cells |
| Upregulation of cancer testis antigens (CTAs) | ||
| Upregulation of genes of the MHC presentation pathway | ||
| Reactivation of repetitive elements (including ERVs) | ||
| HDACs | Deacetylase | Upregulation of PD-L1/PD-L2 in cancer cells |
| Upregulation of cancer testis antigens (CTAs) | ||
| Upregulation of genes of the MHC presentation pathway | ||
| Reactivation of repetitive elements | ||
| Upregulation of T cell chemokine expression | ||
| BRD4 | Bromodomain | Downregulation of PD-L1 in cancer cells |
| EP300 | Acetyltransferase Bromodomain | Downregulation of FOXP3 in Tregs |